In the News
Generation Bold Interview with Alzheon CEO Martin Tolar
Alzheon CEO, Martin Tolar MD, PhD, interviews with Adriane Berg of Generation Bold on Alzheimer’s, ALZ-801 and the learnings from previous drug failures. Click below to listen [...]
Exponential: Martin Tolar
This week on Exponential: Alzheimer’s is a disease that is claiming more and more people, and so far little progress has been made either on a [...]
Alzheon updates on precision medicine approach to treating AD
The American biotech firm Alzheon has unveiled data being presented at the Alzheimer’s Association International Conference (AAIC), in London. The company is conducting a Phase III [...]
Alzheon says data backs potential of Alzheimer’s candidate
US biotech points to new analysis of phase III results for tramiprosate Four years ago, US biotech Alzheon took a gamble on Alzheimer's candidate tramiprosate, thinking [...]
Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013. This research and development has [...]
‘Gene-dose’ effect for Alzheon’s ALZ-801, a drug targeting Alzheimer’s disease
Closely-held US biotech firm Alzheon has announced the publication of data that shows for the first time a ‘gene-dose’ effect for a drug targeting Alzheimer’s disease to [...]
A Little-Known Drug Company Could Have The Answer For Some Alzheimer’s Patients
Alzheon plans to start a multi-center (U.S. and international) Phase 3 trial in 500 mild APOE4/4 homozygous patients next year, with a second trial to start [...]
Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII
Tramiprosate, like so many others, could have been consigned to the scrap heap of once-promising AD meds that didn’t quite make the grade, never to be [...]
Press Releases
Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis
Inhibition of Amyloid Toxicity Represents the Only Clinically Validated Approach for Slowing Progression of Alzheimer’s Disease
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease
Study to Confirm ALZ-801 Effects on Cognition and Function in High-Risk Patients with APOE4/4 Genotype
Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain
Assay Builds on Alzheon’s Research to Detect and Quantify Soluble Oligomers, and Enhances Phase 2 and Phase 3 Alzheimer’s Studies with Oral ALZ-801.
Alzheon to Present at H.C. Wainwright Global Life Sciences Conference
Dr. Martin Tolar, CEO of Alzheon will Present an Overview of Oral Anti-amyloid ALZ-801 Phase 3 Program at the H.C. Wainwright Global Life Sciences Virtual Conference.
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit
Dr. Martin Tolar to Provide an Update on Alzheon’s ALZ-801 Phase 3 Program and Join Panel Discussion on Current Research in Alzheimer’s Disease.
Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease
Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials.